• español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo UVaDOCComunidadesPor fecha de publicaciónAutoresMateriasTítulos

    Mi cuenta

    Acceder

    Estadísticas

    Ver Estadísticas de uso

    Compartir

    Ver ítem 
    •   UVaDOC Principal
    • PRODUCCIÓN CIENTÍFICA
    • Departamentos
    • Dpto. Medicina, Dermatología y Toxicología
    • DEP52 - Artículos de revista
    • Ver ítem
    •   UVaDOC Principal
    • PRODUCCIÓN CIENTÍFICA
    • Departamentos
    • Dpto. Medicina, Dermatología y Toxicología
    • DEP52 - Artículos de revista
    • Ver ítem
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Por favor, use este identificador para citar o enlazar este ítem:https://uvadoc.uva.es/handle/10324/68141

    Título
    Trends in targeted therapy usage in inflammatory bowel disease: TRENDY study of ENEIDA
    Autor
    Gómez Labrador, Celia
    Ricart, Elena
    Iborra, Marisa
    Iglesias, Eva
    Martín Arranz, María Dolores
    De Castro, Luisa
    De Francisco, Ruth
    García Alonso, Francisco JavierAutoridad UVA
    Sanahuja, Ana
    Gargallo Puyuelo, Carla J.
    Mesonero, Francisco
    Casanova, María José
    Mañosa, Míriam
    Rivero, Montserrat
    Calvo, Marta
    Sierra Ausin, Mónica
    González Muñoza, Carlos
    Calvet, Xavier
    García López, Santiago
    Guardiola, Jordi
    Arias García, Lara
    Márquez Mosquera, Lucía
    Gutiérrez, Ana
    Zabana, Yamile
    Navarro Llavat, Mercè
    Lorente Poyatos, Rufo
    Piqueras, Marta
    Torrealba, Leyanira
    Bermejo, Fernando
    Ponferrada Díaz, Ángel
    Pérez Calle, José L.
    Barreiro de Acosta, Manuel
    Tejido, Coral
    Cabriada, José Luis
    Marín Jiménez, Ignacio
    Roncero, Óscar
    Ber, Yolanda
    Fernández Salazar, Luis IgnacioAutoridad UVA
    Camps Aler, Blau
    Lucendo, Alfredo J.
    Llaó, Jordina
    Bujanda, Luis
    Muñoz Villafranca
    Domènech, Eugeni
    Chaparro, María
    Gisbert, Javier P.
    Año del Documento
    2024
    Editorial
    MDPI
    Descripción
    Producción Científica
    Documento Fuente
    Pharmaceutics, 2024, Vol. 16, Nº. 5, 629
    Resumen
    Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn’s disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.
    Materias (normalizadas)
    Biologicals
    Productos biológicos
    Drugs
    Medicamentos
    Drug development
    Biopharmaceutics
    Pharmaceutical biotechnology
    Biotecnologia farmacèutica
    Inflammatory bowel diseases
    Enfermedad inflamatoria intestinal
    Crohn's disease
    Crohn, Enfermedad de
    Intestines - Diseases
    Intestinos - Enfermedades
    Ulcerative colitis
    Colitis ulcerosa
    Pharmacology
    Gastroenterology
    Materias Unesco
    3209 Farmacología
    32 Ciencias Médicas
    3205.03 Gastroenterología
    ISSN
    1999-4923
    Revisión por pares
    SI
    DOI
    10.3390/pharmaceutics16050629
    Nota
    Este estudio recibió financiación para la iInvestigación de Galápagos y de la Asociación Española de Gastroenterología.
    Version del Editor
    https://www.mdpi.com/1999-4923/16/5/629
    Propietario de los Derechos
    © 2024 The authors
    Idioma
    eng
    URI
    https://uvadoc.uva.es/handle/10324/68141
    Tipo de versión
    info:eu-repo/semantics/publishedVersion
    Derechos
    openAccess
    Aparece en las colecciones
    • DEP52 - Artículos de revista [181]
    Mostrar el registro completo del ítem
    Ficheros en el ítem
    Nombre:
    Trends-in-Targeted-Therapy.pdf
    Tamaño:
    1.761Mb
    Formato:
    Adobe PDF
    Thumbnail
    Visualizar/Abrir
    Atribución 4.0 InternacionalLa licencia del ítem se describe como Atribución 4.0 Internacional

    Universidad de Valladolid

    Powered by MIT's. DSpace software, Version 5.10